Paper36980630
Overview of Trop-2 in Cancer: From Pre-Clinical Studies to Future Directions in Clinical Settings.
Lombardi P and 9 others. Cancers (Basel), 2023. Cited by 56 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Overview of Trop-2 in Cancer: From Pre-Clinical Studies to Future Directions in Clinical Settings. Papers, record 36980630. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36980630
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Overview of Trop-2 in Cancer: From Pre-Clinical Studies to Future Directions in Clinical Settings.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| NA | Gilead Sciences (Italy) | PubMed |
Source PubMed
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT07343453 | A Single-Arm, Phase II Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan in Second-Line and Subsequent Treatments for Advanced Thymic Epithelial Tumors | Background |
Source ClinicalTrials.gov
References75
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 28709407 | Trop2 enhances invasion of thyroid cancer by inducing MMP2 through ERK and JNK pathways. | BMC Cancer | 2017 | https://conductscience.org/library/papers/28709407 | PubMed |
| 2 | 26000093 | Trop2 and its overexpression in cancers: regulation and clinical/therapeutic implications. | Genes Cancer | 2015 | https://conductscience.org/library/papers/26000093 | PubMed |
| 3 | 18930986 | TROP2 expression as prognostic marker for gastric carcinoma. | J Clin Pathol | 2009 | https://conductscience.org/library/papers/18930986 | PubMed |
| 4 | 19429791 | Potential hepatic stem cells reside in EpCAM+ cells of normal and injured mouse liver. | Development | 2009 | https://conductscience.org/library/papers/19429791 | PubMed |
| 5 | 25431858 | Discovery of cytotoxic dolastatin 10 analogues with N-terminal modifications. | J Med Chem | 2014 | https://conductscience.org/library/papers/25431858 | PubMed |
| 6 | 27582525 | RN927C, a Site-Specific Trop-2 Antibody-Drug Conjugate (ADC) with Enhanced Stability, Is Highly Efficacious in Preclinical Solid Tumor Models. | Mol Cancer Ther | 2016 | https://conductscience.org/library/papers/27582525 | PubMed |
| 7 | 21970857 | Loss of Trop2 promotes carcinogenesis and features of epithelial to mesenchymal transition in squamous cell carcinoma. | Mol Cancer Res | 2011 | https://conductscience.org/library/papers/21970857 | PubMed |
| 8 | 7029529 | Human trophoblast cell-surface antigens defined by monoclonal antibodies. | Proc Natl Acad Sci U S A | 1981 | https://conductscience.org/library/papers/7029529 | PubMed |
| 9 | 2395876 | Molecular cloning of cDNA for the human tumor-associated antigen CO-029 and identification of related transmembrane antigens. | Proc Natl Acad Sci U S A | 1990 | https://conductscience.org/library/papers/2395876 | PubMed |
| 10 | 26106073 | Enhanced Delivery of SN-38 to Human Tumor Xenografts with an Anti-Trop-2-SN-38 Antibody Conjugate (Sacituzumab Govitecan). | Clin Cancer Res | 2015 | https://conductscience.org/library/papers/26106073 | PubMed |
| 11 | 21551320 | Expression of Trop2 cell surface glycoprotein in normal and tumor tissues: potential implications as a cancer therapeutic target. | J Histochem Cytochem | 2011 | https://conductscience.org/library/papers/21551320 | PubMed |
| 12 | 28548889 | Therapy of Advanced Non-Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan. | J Clin Oncol | 2017 | https://conductscience.org/library/papers/28548889 | PubMed |
| 13 | 10328271 | HIKE, a candidate protein binding site for PH domains, is a major regulatory region of Gbeta proteins. | Proteins | 1999 | https://conductscience.org/library/papers/10328271 | PubMed |
| 14 | 27022065 | Trop-2 Induces Tumor Growth Through AKT and Determines Sensitivity to AKT Inhibitors. | Clin Cancer Res | 2016 | https://conductscience.org/library/papers/27022065 | PubMed |
| 15 | 16552761 | Control of cell migration in the zebrafish lateral line: implication of the gene "tumour-associated calcium signal transducer," tacstd. | Dev Dyn | 2006 | https://conductscience.org/library/papers/16552761 | PubMed |
| 16 | 29276405 | Prognostic role and clinical significance of trophoblast cell surface antigen 2 in various carcinomas. | Cancer Manag Res | 2017 | https://conductscience.org/library/papers/29276405 | PubMed |
| 17 | 34519889 | ImmunoPET of trophoblast cell-surface antigen 2 (Trop-2) expression in pancreatic cancer. | Eur J Nucl Med Mol Imaging | 2022 | https://conductscience.org/library/papers/34519889 | PubMed |
| 18 | 25523132 | Trop2: from development to disease. | Dev Dyn | 2015 | https://conductscience.org/library/papers/25523132 | PubMed |
| 19 | 26015409 | Trop-2 is up-regulated in invasive prostate cancer and displaces FAK from focal contacts. | Oncotarget | 2015 | https://conductscience.org/library/papers/26015409 | PubMed |
| 20 | 22562244 | The Trop-2 signalling network in cancer growth. | Oncogene | 2013 | https://conductscience.org/library/papers/22562244 | PubMed |
Cited by42
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 56 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42729864 | Structure and function of therapeutic antibodies approved by the US FDA in 2025. | Antib Ther | 2026 | https://conductscience.org/library/papers/42729864 | PubMed |
| 42656367 | Adipocyte-derived estrogen signaling influences TROP2 expression in ERα-positive breast cancer. | Front Endocrinol (Lausanne) | 2026 | https://conductscience.org/library/papers/42656367 | PubMed |
| 42653691 | Antibody-Drug Conjugates Targeting HER2 and Trop-2: A New Force in Precision Treatment for Solid Tumors. | Pharmaceuticals (Basel) | 2026 | https://conductscience.org/library/papers/42653691 | PubMed |
| 42482759 | Datopotamab deruxtecan in solid tumors: Recent research progress and clinical applications. | Front Oncol | 2026 | https://conductscience.org/library/papers/42482759 | PubMed |
| 42375351 | Antibody-drug conjugates in gynecologic malignancies: breakthroughs, challenges, and future directions. | Front Immunol | 2026 | https://conductscience.org/library/papers/42375351 | PubMed |
| 42352327 | A Pyrone Glucoside from Maerua angolensis Induces Caspase-Dependent Apoptosis and Targets AKT1, PARP-1, and Caspase-7 in Triple-Negative Breast Cancer. | Biomolecules | 2026 | https://conductscience.org/library/papers/42352327 | PubMed |
| 42297906 | Pan-cancer multi-omic integration of Trop2 reveals biological determinants and translational implications for ADC therapy. | NPJ Precis Oncol | 2026 | https://conductscience.org/library/papers/42297906 | PubMed |
| 42294312 | Trop-2 expression is associated with poor survival in pleural mesothelioma. | Front Oncol | 2026 | https://conductscience.org/library/papers/42294312 | PubMed |
| 42142358 | TROPION-Urothelial03: a phase II/III study of datopotamab deruxtecan (Dato-DXd) for locally advanced or metastatic urothelial carcinoma. | Future Oncol | 2026 | https://conductscience.org/library/papers/42142358 | PubMed |
| 41900872 | Receptor-Mediated Drug Delivery: Redefining Targeted Drug Conjugates in Oncology. | Pharmaceutics | 2026 | https://conductscience.org/library/papers/41900872 | PubMed |
| 41867620 | Exploring Trop-2-Nanobody PPI Interactions through Molecular Dynamics Simulations and Biovalidations. | ACS Omega | 2026 | https://conductscience.org/library/papers/41867620 | PubMed |
| 41621018 | Clinical advances and challenges of antibody-mediated targeted drug delivery in breast cancer therapeutics. | Discov Oncol | 2026 | https://conductscience.org/library/papers/41621018 | PubMed |
| 41613789 | A Holistic Review of Oncological Drug Targets and Trajectories of Resistance in Cancer Therapy. | Oncol Res | 2026 | https://conductscience.org/library/papers/41613789 | PubMed |
| 41533296 | Prognostic impact of TROP2 in adenocarcinoma of the esophageal junction and stomach. | Clin Transl Oncol | 2026 | https://conductscience.org/library/papers/41533296 | PubMed |
| 41427810 | Predictive Biomarkers of Antibody-Drug Conjugate Efficacy for Solid Tumors: Current Challenges and the Potential Role of Quantitative Proteomics. | Clin Cancer Res | 2026 | https://conductscience.org/library/papers/41427810 | PubMed |
| 41426858 | Diagnostic Significance of Trophoblast Cell Surface Antigen-2 Expression in Benign and Malignant Thyroid Lesions. | Cureus | 2025 | https://conductscience.org/library/papers/41426858 | PubMed |
| 41286743 | Real-world insights into the prevalence and prognostic significance of trophoblast cell-surface antigen 2 and folate receptor alpha in uterine carcinosarcoma. | BMC Cancer | 2025 | https://conductscience.org/library/papers/41286743 | PubMed |
| 41280245 | Trop2 expression, p16 expression status, and histologic subtype in carcinoma of the uterine cervix. | Pathol Oncol Res | 2025 | https://conductscience.org/library/papers/41280245 | PubMed |
| 41272532 | Establishment of a new method for detection of TROP2-positive circulating tumor cells in breast cancer. | BMC Cancer | 2025 | https://conductscience.org/library/papers/41272532 | PubMed |
| 41014400 | Baseline hemoglobin and neutrophil-to-lymphocyte ratio as prognostic biomarkers in patients with metastatic triple negative breast cancer treated with sacituzumab govitecan in second line and beyond: a real-world analysis. | Breast Cancer Res Treat | 2025 | https://conductscience.org/library/papers/41014400 | PubMed |
Genes33
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36980630
GET https://conductscience.org/api/papers/v1/36980630/references?page=2